ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more

Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

658.8M

52 Wk Range

$0.46 - $7.13

Previous Close

$2.19

Open

$2.19

Volume

918,759

Day Range

$2.13 - $2.25

Enterprise Value

42.5M

Cash

271.7M

Avg Qtr Burn

-27.94M

Insider Ownership

25.38%

Institutional Own.

28.56%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.